Role of carnitine in disease

Nutrition and Metabolism

Volumn 7, Issue , 2010, Pages

  Flanagan, Judith L ^a   Simmons, Peter A ^b   Vehige, Joseph ^b   Willcox, Mark Dp ^a,c   Garrett, Qian ^a,c  

^a BRIEN HOLDEN VISION INSTITUTE   (Australia)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; CARNITINE; CARNITINE PALMITOYLTRANSFERASE I; CYCLOSPORIN A; VALPROIC ACID;

AGING; ALZHEIMER DISEASE; AMINO ACID METABOLISM; BIOAVAILABILITY; BIOSYNTHESIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARNITINE DEFICIENCY; DEMENTIA; DIABETES MELLITUS; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY INTAKE; DRY EYE; ENDOCRINE DISEASE; ENERGY EXPENDITURE; ENERGY YIELD; FATTY ACID METABOLISM; GENE MUTATION; GLUCOSE INTOLERANCE; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNE RESPONSE; INJURY; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; MALNUTRITION; NEPHROTOXICITY; NERVE CONDUCTION; NEUROMUSCULAR DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; NUTRITION; OBESITY; OSTEOLYSIS; RETINA DISEASE; REVIEW; SEPSIS; UREMIA; VEGETARIAN; WOUND HEALING;

EID: 77950837764     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-7-30     Document Type: Review

References (168)

1. Carnitine: an overview of its role in preventive medicine. BS Kendler, Prev Med 1986 15 373 390 10.1016/0091-7435(86)90005-8 3532087
2. Primary and secondary disorders of carnitine metabolism. DC De Vivo I Tein, Int Pediatr 1990 5 8
3. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. CJ Rebouche, Ann N Y Acad Sci 2004 1033 30 41 10.1196/annals.1320.003 15591001
4. Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. CJ Rebouche CA Chenard, J Nutr 1991 121 539 546 2007906
5. Obesity, inflammation, and the potential application of pharmaconutrition. MC Cave RT Hurt TH Frazier PJ Matheson RN Garrison CJ McClain SA McClave, Nutr Clin Pract 2008 23 16 34 10.1177/011542650802300116 18203961
6. Carnitine function and requirements during the life cycle. CJ Rebouche, Faseb J 1992 6 3379 3386 1464372
7. Carnitine status of lactoovovegetarians and strict vegetarian adults and children. KA Lombard AL Olson SE Nelson CJ Rebouche, Am J Clin Nutr 1989 50 301 306 2756917
8. Carnitine biosynthesis in mammals. FM Vaz RJ Wanders, Biochem J 2002 361 417 429 10.1042/0264-6021:3610417 11802770
9. C Rebouche, Carnitine: Modern Nutrition in Health and Disease Philadelphia: Lippincott, Williams and Wilkins, Shils M, Shike M, Ross A, et al, 2006 537 544
10. Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency. C Angelini C Trevisan G Isaya G Pegolo L Vergani, Clin Biochem 1987 20 1 7 10.1016/S0009-9120(87)80090-5 3552320
11. Carnitine and hemodialysis. G Bellinghieri D Santoro M Calvani A Mallamace V Savica, Am J Kidney Dis 2003 41 116 122 10.1053/ajkd.2003.50099 12612967
12. Carnitine metabolism and its regulation in microorganisms and mammals. CJ Rebouche H Seim, Annu Rev Nutr 1998 18 39 61 10.1146/annurev.nutr.18.1.39 9706218
13. L-carnitine in dialysis patients. S Ahmad, Semin Dial 2001 14 209 217 10.1046/j.1525-139X.2001.00055.x 11422928
14. Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). SR Srinivas PD Prasad NS Umapathy V Ganapathy PS Shekhawat, Am J Physiol Gastrointest Liver Physiol 2007 293 1046 1053 10.1152/ajpgi.00233.2007 17855766
15. Current Concepts in Carnitine Research. GD Lopaschuk, Atlanta 1991
16. Carnitine deficiency syndromes. GN Breningstall, Pediatr Neurol 1990 6 75 81 10.1016/0887-8994(90)90037-2 2187442
17. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. MC Orngreen DB Olsen J Vissing, Neurology 2002 59 1046 1051 10.1001/archneur.59.6.1046 12370460
18. Turning down lipid oxidation during heavy exercise - what is the mechanism? K Sahlin EK Sallstedt D Bishop M Tonkonogi, J Physiol Pharmacol 2008 59 Suppl 7 19 30 19258655
19. Carnitine: an osmolyte that plays a metabolic role. G Peluso A Barbarisi V Savica E Reda R Nicolai P Benatti M Calvani, J Cell Biochem 2000 80 1 10 10.1002/1097-4644(20010101)80:1<1::AID-JCB10>3.0.CO;2-W 11029749
20. Characteristics of L-carnitine transport by lactating rat mammary tissue. DB Shennan A Grant RR Ramsay C Burns VA Zammit, Biochim Biophys Acta 1998 1393 49 56 9714731 (Pubitemid 28495589)
21. Carnitine transporter OCTN2 mutations in systemic primary carnitine deficiency: a novel Arg169Gln mutation and a recurrent Arg282ter mutation associated with an unconventional splicing abnormality. B Burwinkel J Kreuder S Schweitzer M Vorgerd K Gempel KD Gerbitz MW Kilimann, Biochem Biophys Res Commun 1999 261 484 487 10.1006/bbrc.1999.1060 10425211
22. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Y Wang J Ye V Ganapathy N Longo, Proc Natl Acad Sci USA 1999 96 2356 2360 10.1073/pnas.96.5.2356 10051646 (Pubitemid 29117919)
23. L-carnitine supplementation in the dialysis population: are Australian patients missing out? SE Reuter RJ Faull AM Evans, Nephrology (Carlton) 2008 13 3 16 18199095
24. Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency. SD Cederbaum S Koo-McCoy I Tein BY Hsu A Ganguly E Vilain K Dipple L Cvitanovic-Sojat C Stanley, Mol Genet Metab 2002 77 195 201 10.1016/S1096- 7192(02)00169-5 12409266
25. Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2. U Spiekerkoetter G Huener T Baykal M Demirkol M Duran R Wanders J Nezu E Mayatepek, J Inherit Metab Dis 2003 26 613 615 10.1023/A:1025968502527 14605509
26. A missense mutation in the OCTN2 gene associated with residual carnitine transport activity. Y Wang MA Kelly TM Cowan N Longo, Hum Mutat 2000 15 238 245 10.1002/(SICI)1098-1004(200003)15:3<238::AID-HUMU4>3.0.CO;2-3 10679939
27. Primary and secondary carnitine deficiency syndromes. R Pons DC De Vivo, J Child Neurol 1995 10 Suppl 2 8 24 8576570
28. Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. A Koizumi J Nozaki T Ohura T Kayo Y Wada J Nezu R Ohashi I Tamai Y Shoji G Takada S Kibira T Matsuishi A Tsuji, Hum Mol Genet 1999 8 2247 2254 10.1093/hmg/8.12.2247 10545605
29. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. J Nezu I Tamai A Oku R Ohashi H Yabuuchi N Hashimoto H Nikaido Y Sai A Koizumi Y Shoji G Takada T Matsuishi M Yoshino H Kato T Ohura G Tsujimoto J Hayakawa M Shimane A Tsuji, Nat Genet 1999 21 91 94 10.1038/5030 9916797
30. A case of early diagnosed carnitine deficiency presenting with respiratory symptoms. M Erguven O Yilmaz S Koc S Caki Y Ayhan M Donmez G Dolunay, Ann Nutr Metab 2007 51 331 334 10.1159/000107675 17726310
31. Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency. E Mayatepek J Nezu I Tamai A Oku M Katsura M Shimane A Tsuji, Hum Mutat 2000 15 118 10.1002/(SICI)1098- 1004(200001)15:1<118::AID-HUMU28>3.0.CO;2-8 10612840
32. Mutations in novel organic cation transporter (OCTN2), an organic cation/carnitine transporter, with differential effects on the organic cation transport function and the carnitine transport function. P Seth X Wu W Huang FH Leibach V Ganapathy, J Biol Chem 1999 274 33388 33392 10.1074/jbc.274.47.33388 10559218
33. Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient cellular carnitine uptake in primary carnitine deficiency. NL Tang V Ganapathy X Wu J Hui P Seth PM Yuen RJ Wanders TF Fok NM Hjelm, Hum Mol Genet 1999 8 655 660 10.1093/hmg/8.4.655 10072434
34. Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review. E Sigauke D Rakheja K Kitson MJ Bennett, Lab Invest 2003 83 1543 1554 10.1097/01.LAB.0000098428.51765.83 14615409
35. Current status of genetics research in inflammatory bowel disease. S Vermeire P Rutgeerts, Genes Immun 2005 6 637 645 16107869
36. Fatty acid oxidation disorders. P Rinaldo D Matern MJ Bennett, Annu Rev Physiol 2002 64 477 502 10.1146/annurev.physiol.64.082201.154705 11826276
37. Clinical and biochemical features of fatty acid oxidation disorders. P Rinaldo K Raymond A al-Odaib MJ Bennett, Curr Opin Pediatr 1998 10 615 621 10.1097/00008480-199810060-00014 9848022
38. Primary and secondary alterations of neonatal carnitine metabolism. F Scaglia N Longo, Semin Perinatol 1999 23 152 161 10.1016/S0146-0005(99)80047-0 10331466
39. Treatment of carnitine deficiency. SC Winter, J Inherit Metab Dis 2003 26 171 180 10.1023/A:1024433100257 12889658
40. Carnitine metabolism and deficiency syndromes. CJ Rebouche AG Engel, Mayo Clin Proc 1983 58 533 540 6348429
41. Carnitine deficiency: Primary and secondary syndromes. G Famularo F Matricardi E Nucera G Santini C De Simone, Carnitine Today Austin, TX: R.G. Landes Company, De Simone CFG, 1997 119 161
42. Primary carnitine deficiency. HR Scholte R Rodrigues Pereira PC de Jonge IE Luyt-Houwen M Hedwig M Verduin JD Ross, J Clin Chem Clin Biochem 1990 28 351 357 2199596
43. History of L-carnitine: implications for renal disease. M Matera G Bellinghieri G Costantino D Santoro M Calvani V Savica, J Ren Nutr 2003 13 2 14 10.1053/jren.2003.50010 12563618
44. Effect of L-carnitine on the serum lipoproteins and HDL-C subclasses in hemodialysis patients. H Argani M Rahbaninoubar A Ghorbanihagjo Z Golmohammadi N Rashtchizadeh, Nephron Clin Pract 2005 101 174 179 10.1159/000087411 16103722
45. Isolation and characterization of cDNA and genomic clones encoding human muscle type carnitine palmitoyltransferase I. N Yamazaki Y Shinohara A Shima Y Yamanaka H Terada, Biochim Biophys Acta 1996 1307 157 161 8679700
46. Structural features of the gene encoding human muscle type carnitine palmitoyltransferase I. N Yamazaki Y Yamanaka Y Hashimoto Y Shinohara A Shima H Terada, FEBS Lett 1997 409 401 406 10.1016/S0014-5793(97)00561-9 9224698
47. Substitutions of three amino acids in human heart/muscle type carnitine palmitoyltransferase I caused by single nucleotide polymorphisms. N Yamazaki T Matsuo M Kurata M Suzuki T Fujiwaki S Yamaguchi H Terada Y Shinohara, Biochem Genet 2008 46 54 63 10.1007/s10528-007-9129-3 17987377
48. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. M Deschauer T Wieser S Zierz, Arch Neurol 2005 62 37 41 10.1001/archneur.62.1.37 15642848
49. Autopsy case of the neonatal form of carnitine palmitoyltransferase-II deficiency triggered by a novel disease-causing mutation del1737C. S Semba H Yasujima T Takano H Yokozaki, Pathol Int 2008 58 436 441 10.1111/j.1440-1827. 2008.02250.x 18577113
50. Functional significance of cell volume regulatory mechanisms. F Lang GL Busch M Ritter H Volkl S Waldegger E Gulbins D Haussinger, Physiol Rev 1998 78 247 306 9457175 (Pubitemid 28070981)
51. L-carnitine in dialysed patients: the choice of dosage regimen. E Berard A Iordache D Barrillon J Bayle, Int J Clin Pharmacol Res 1995 15 127 133 8847154
52. Carnitine metabolism in patients with chronic renal failure: effect of L-carnitine supplementation. C Wanner S Forstner-Wanner C Rossle P Furst P Schollmeyer WH Horl, Kidney Int Suppl 1987 22 132 135 3480977
53. Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects. C Wanner WH Horl, Nephron 1988 50 89 102 10.1159/000185137 3065666
54. Carnitine replacement in end-stage renal disease and hemodialysis. M Calvani P Benatti A Mancinelli S D'Iddio V Giordano A Koverech A Amato EP Brass, Ann N Y Acad Sci 2004 1033 52 66 10.1196/annals.1320.005 15591003
55. Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy. GJ Handelman, Blood Purif 2006 24 140 142 10.1159/000089450 16361854
56. Protective effect of L-propionylcarnitine on cyclosporine-induced nephrotoxicity. A Bertelli L Giovannini R Palla M Migliori V Panichi B Andreini, Drugs Exp Clin Res 1995 21 221 228 8907697
57. Protective effect of L-propionylcarnitine in chronic cyclosporine-a induced nephrotoxicity. N Origlia M Migliori V Panichi C Filippi A Bertelli A Carpi L Giovannini, Biomed Pharmacother 2006 60 77 81 10.1016/j.biopha.2005.06. 014 16472963
58. Is Oral L: -Acyl-Carnitine an Effective Therapy for Hepatic Encephalopathy? Review of the Literature. NJ Shores EB Keeffe, Dig Dis Sci 2008 18270833
59. Acetyl-L: -Carnitine Treatment in Minimal Hepatic Encephalopathy. M Malaguarnera MP Gargante E Cristaldi M Vacante C Risino L Cammalleri G Pennisi L Rampello, Dig Dis Sci 2008
60. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat. G Therrien C Rose J Butterworth RF Butterworth, Hepatology 1997 25 551 556 10.1002/hep.510250310 9049197
61. Increased blood ammonia in hypoxia during exercise in humans. H Casas B Murtra M Casas J Ibanez JL Ventura A Ricart F Rodriguez G Viscor L Palacios T Pages R Rama, J Physiol Biochem 2001 57 303 312 10.1007/BF03179824 12005033
62. L-carnitine administration reverses acute mental status changes in a chronic hemodialysis patient with hepatitis C infection. WJ DaVanzo ME Ullian, Clin Nephrol 2002 57 402 405 12036203
63. L-Carnitine in the treatment of mild or moderate hepatic encephalopathy. M Malaguarnera G Pistone M Astuto S Dell'Arte G Finocchiaro E Lo Giudice G Pennisi, Dig Dis 2003 21 271 275 10.1159/000073347 14571103
64. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. M Malaguarnera G Pistone M Astuto I Vecchio R Raffaele E Lo Giudice L Rampello, Dig Dis Sci 2006 51 2242 2247 10.1007/s10620-006-9187-0 17080254
65. Effects of L-carnitine in patients with hepatic encephalopathy. M Malaguarnera G Pistone R Elvira C Leotta L Scarpello R Liborio, World J Gastroenterol 2005 11 7197 7202 16437672
66. Pathogenetic mechanisms of acute hepatic encephalopathy. KD Mullen R Gacad, New Horiz 1994 2 505 511 7804799
67. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. JW Pettegrew J Levine RJ McClure, Mol Psychiatry 2000 5 616 632 10.1038/sj.mp.4000805 11126392
68. Deficiency of carnitine in cachectic cirrhotic patients. D Rudman CW Sewell JD Ansley, J Clin Invest 1977 60 716 723 10.1172/JCI108824 893675
69. Fatty liver in the rat after prolonged intake of ethanol with a nutritionally adequate new liquid diet. LM DeCarli CS Lieber, J Nutr 1967 91 331 336 6021815
70. Alcohol and its relation to liver damage. G Klatskin, Gastroenterology 1961 41 443 451 14456652
71. Ameliorating effects of carnitine and its precursors on alcohol-induced fatty liver. DS Sachan TH Rhew RA Ruark, Am J Clin Nutr 1984 39 738 744 6424429
72. Dose-dependent lipotropic effect of carnitine in chronic alcoholic rats. TH Rhew DS Sachan, J Nutr 1986 116 2263 2269 3794832
73. Inhibitory effects of alcohol on intestinal amino acid transport in vivo and in vitro. Y Israel I Salazar E Rosenmann, J Nutr 1968 96 499 504 5699991
74. Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity. FP Kuhajda GV Ronnett, Curr Opin Investig Drugs 2007 8 312 317 17458181
75. Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight. S Aja LE Landree AM Kleman SM Medghalchi A Vadlamudi JM McFadden A Aplasca J Hyun E Plummer K Daniels M Kemm CA Townsend JN Thupari FP Kuhajda TH Moran GV Ronnett, Am J Physiol Regul Integr Comp Physiol 2008 294 352 361 18056987
76. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. S Obici Z Feng A Arduini R Conti L Rossetti, Nat Med 2003 9 756 761 10.1038/nm873 12754501
77. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. A Pocai TK Lam S Obici R Gutierrez-Juarez ED Muse A Arduini L Rossetti, J Clin Invest 2006 116 1081 1091 10.1172/JCI26640 16528412
78. Molecular disruption of hypothalamic nutrient sensing induces obesity. W He TK Lam S Obici L Rossetti, Nat Neurosci 2006 9 227 233 10.1038/nn1626 16415870
79. C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism. LE Landree AL Hanlon DW Strong G Rumbaugh IM Miller JN Thupari EC Connolly RL Huganir C Richardson LA Witters FP Kuhajda GV Ronnett, J Biol Chem 2004 279 3817 3827 10.1074/jbc.M310991200 14615481
80. Central administration of oleic acid inhibits glucose production and food intake. S Obici Z Feng K Morgan D Stein G Karkanias L Rossetti, Diabetes 2002 51 271 275 10.2337/diabetes.51.2.271 11812732
81. Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J Hao W Shen C Tian Z Liu J Ren C Luo J Long E Sharman J Liu, J Cell Mol Med 2008 18410524
82. Glutaric aciduria; a "new" disorder of amino acid metabolism. SI Goodman SP Markey PG Moe BS Miles CC Teng, Biochem Med 1975 12 12 21 10.1016/0006-2944(75)90091-5 1137568
83. Pathomechanisms of neurodegeneration in glutaryl-CoA dehydrogenase deficiency. S Kolker DM Koeller JG Okun GF Hoffmann, Ann Neurol 2004 55 7 12 10.1002/ana.10784 14705106 (Pubitemid 38067355)
84. Diagnosis and management of glutaric aciduria type I. I Baric J Zschocke E Christensen M Duran SI Goodman JV Leonard E Muller DH Morton A Superti-Furga GF Hoffmann, J Inherit Metab Dis 1998 21 326 340 10.1023/A:1005390105171 9700590
85. Prevention of cerebral palsy in glutaric aciduria type 1 by dietary management. AA Monavari ER Naughten, Arch Dis Child 2000 82 67 70 10.1136/adc.82.1.67 10630918
86. Type I glutaric aciduria, part 1: natural history of 77 patients. KA Strauss EG Puffenberger DL Robinson DH Morton, Am J Med Genet C Semin Med Genet 2003 121C 38 52 10.1002/ajmg.c.20007 12888985
87. Nutrition support for glutaric acidemia type I. S Yannicelli F Rohr ML Warman, J Am Diet Assoc 1994 94 183 188 10.1016/0002-8223(94)90245-3 8300996
88. Urinary excretion of carnitine in patients with hyperthyroidism and hypothyroidism: augmentation by thyroid hormone. M Maebashi N Kawamura M Sato A Imamura K Yoshinaga, Metabolism 1977 26 351 356 10.1016/0026-0495(77)90101-9 846404
89. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. AA Sima, CNS Drugs 2007 21 Suppl 1 13 23 discussion 45-16 10.2165/00023210-200721001-00003 17696589
90. Effect of endocrine pancreas allotransplantation on diabetic nerve dysfunction. WJ Tze AA Sima J Tai, Metabolism 1985 34 721 725 10.1016/0026-0495(85)90021-6 3927109
91. Improvement in nerve conduction following treatment in newly diagnosed diabetics. JD Ward CG Barnes DJ Fisher JD Jessop RW Baker, Lancet 1971 1 428 430 10.1016/S0140-6736(71)92415-9 4100402
92. C-peptide and diabetic neuropathy. AA Sima, Expert Opin Investig Drugs 2003 12 1471 1488 10.1517/13543784.12.9.1471 12943492
93. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. AA Sima V Bril V Nathaniel TA McEwen MB Brown SA Lattimer DA Greene, N Engl J Med 1988 319 548 555 3136331
94. Metabolic response to injury and sepsis: changes in protein metabolism. G Biolo G Toigo B Ciocchi R Situlin F Iscra A Gullo G Guarnieri, Nutrition 1997 13 52S 57S 10.1016/S0899-9007(97)00206-2 9290110
95. Carnitine and its congeners: a metabolic pathway to the regulation of immune response and inflammation. G Famularo C De Simone V Trinchieri L Mosca, Ann N Y Acad Sci 2004 1033 132 138 10.1196/annals.1320.012 15591010
96. A new era for carnitine? G Famularo C De Simone, Immunol Today 1995 16 211 213 10.1016/0167-5699(95)80159-6 7779248
97. Carnitine deprivation adversely affects cardiovascular response to bacterial endotoxin (LPS) in the anesthetized neonatal pig. D Penn L Zhang PJ Bobrowski M Quinn X Liu KH McDonough, Shock 1998 10 377 382 10.1097/00024382- 199811000-00012 9840655
98. Carnitine deprivation adversely affects cardiac performance in the lipopolysaccharide- and hypoxia/reoxygenation-stressed piglet heart. D Penn L Zhang PJ Bobrowski M Quinn KH McDonough, Shock 1999 11 120 126 10.1097/00024382-199902000-00009 10030799
99. Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function. S Trumbeckaite JR Opalka C Neuhof S Zierz FN Gellerich, Eur J Biochem 2001 268 1422 1429 10.1046/j.1432-1327.2001.02012.x 11231295
100. Myocardial carnitine palmitoyltransferase I as a target for oxidative modification in inflammation and sepsis. S Eaton K Fukumoto G Stefanutti L Spitz VA Zammit A Pierro, Biochem Soc Trans 2003 31 1133 1136 10.1042/BST0311133 14641011
101. Plasma carnitine levels and urinary carnitine excretion during sepsis. G Nanni M Pittiruti I Giovannini G Boldrini P Ronconi M Castagneto, JPEN J Parenter Enteral Nutr 1985 9 483 490 10.1177/0148607185009004483 3928925
102. Urinary excretion of carnitne in burned patients. G Cederblad J Larsson H Nordstrom B Schildt, Burns 1981 8 102 109 10.1016/0305-4179(81)90030-9
103. Rationales for micronutrient supplementation in diabetes. MF McCarty EJ Rubin, Med Hypotheses 1984 13 139 151 10.1016/0306-9877(84)90025-2 6325854
104. The additive effects of carnitine and ascorbic acid on distally burned dorsal skin flap in rats. E Arslan Y Basterzi A Aksoy C Majka S Unal A Sari F Demirkan, Med Sci Monit 2005 11 R176 180 15917712
105. The Effect of L-Carnitine on Wound Healing by Secondary Intention in an Animal Model. S Koybasi Y Taner, Wounds 2005 17 62 66
106. Plasma carnitine levels in children with protein-calorie malnutrition before and after rehabilitation. L Khan MS Bamji, Clin Chim Acta 1977 75 163 166 10.1016/0009-8981(77)90513-7 403033
107. Tissue carnitine deficiency due to dietary lysine dificiency: triglyceride accumulation and concomitant impairment in fatty acid oxidation. L Khan MS Bamji, J Nutr 1979 109 24 31 430211
108. Plasma and urine carnitine levels and carnitine supplementation in children with malnutrition. H Alp Z Orbak F Akcay H Tan H Aksoy, J Trop Pediatr 1999 45 294 296 10.1093/tropej/45.5.294 10584472
109. Prevalence of carnitine depletion in critically ill patients with undernutrition. A Wennberg A Hyltander A Sjoberg B Arfvidsson R Sandstrom I Wickstrom K Lundholm, Metabolism 1992 41 165 171 10.1016/0026-0495(92)90146-2 1736038
110. Plasma carnitine deficiency. Clinical observations in 51 pediatric patients. SC Winter S Szabo-Aczel CJ Curry HT Hutchinson R Hogue A Shug, Am J Dis Child 1987 141 660 665 3578191
111. PPARalpha agonists up-regulate organic cation transporters in rat liver cells. S Luci S Geissler B Konig A Koch GI Stangl F Hirche K Eder, Biochem Biophys Res Commun 2006 350 704 708 10.1016/j.bbrc.2006.09.099 17011512
112. Dietary oxidised fat up regulates the expression of organic cation transporters in liver and small intestine and alters carnitine concentrations in liver, muscle and plasma of rats. A Koch B Konig S Luci GI Stangl K Eder, Br J Nutr 2007 98 882 889 10.1017/S000711450775691X 17524183
113. Vegetarian Diet Affects Genes of Oxidative Metabolism and Collagen Synthesis. H Karlic D Schuster F Varga G Klindert A Lapin A Haslberger M Handschur, Ann Nutr Metab 2008 53 29 32 10.1159/000152871 18772587
114. In the Rat Brain Acetyl-L: -carnitine Treatment Modulates the Expression of Genes Involved in Neuronal Ceroid Lipofuscinosis. G Traina R Bernardi E Cataldo M Macchi M Durante M Brunelli, Mol Neurobiol 2008 18726077
115. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. SE Mole RE Williams HH Goebel, Neurogenetics 2005 6 107 126 10.1007/s10048-005-0218-3 15965709
116. Phenotypic reversal of the btn1 defects in yeast by chloroquine: a yeast model for Batten disease. DA Pearce CJ Carr B Das F Sherman, Proc Natl Acad Sci USA 1999 96 11341 11345 10.1073/pnas.96.20.11341 10500178
117. The effect of acetyl-L-carnitine administration on persons with Down syndrome. SM Pueschel, Res Dev Disabil 2006 27 599 604 10.1016/j.ridd.2004.07. 009 16621446
118. Natural antioxidants in Alzheimer's disease. C Mancuso TE Bates DA Butterfield S Calafato C Cornelius A De Lorenzo AT Dinkova Kostova V Calabrese, Expert Opin Investig Drugs 2007 16 1921 1931 10.1517/13543784.16.12.1921 18042001
119. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. C Ramassamy, Eur J Pharmacol 2006 545 51 64 10.1016/j.ejphar.2006.06.025 16904103
120. Diseases caused by defects of mitochondrial carriers: a review. F Palmieri, Biochim Biophys Acta 2008 1777 564 578 10.1016/j.bbabio.2008.03.008 18406340
121. The Role of Inflammatory Markers in the Cardioprotective Effect of L-Carnitine in L-NAME-Induced Hypertension. JL Miguel-Carrasco A Mate MT Monserrat JL Arias O Aramburu CM Vazquez, Am J Hypertens 2008 18787523
122. Carnitine worsens both injury and recovery of contractile function after transient ischemia in perfused rat heart. R Diaz J Lorita M Soley I Ramirez, J Physiol Biochem 2008 64 1 8 10.1007/BF03168229 18663990
123. Carnitine and its derivatives in cardiovascular disease. MA Arsenian, Prog Cardiovasc Dis 1997 40 265 286 10.1016/S0033-0620(97)80037-0 9406679
124. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. R Ferrari E Merli G Cicchitelli D Mele A Fucili C Ceconi, Ann N Y Acad Sci 2004 1033 79 91 10.1196/annals.1320.007 15591005
125. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. S Iliceto D Scrutinio P Bruzzi G D'Ambrosio L Boni M Di Biase G Biasco PG Hugenholtz P Rizzon, J Am Coll Cardiol 1995 26 380 387 10.1016/0735-1097(95)80010-E 7608438
126. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. P Colonna S Iliceto, Am Heart J 2000 139 124 130 10.1067/mhj.2000.103918 10650326
127. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. G Tarantini D Scrutinio P Bruzzi L Boni P Rizzon S Iliceto, Cardiology 2006 106 215 223 10.1159/000093131 16685128
128. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. RB Singh MA Niaz P Agarwal R Beegum SS Rastogi DS Sachan, Postgrad Med J 1996 72 45 50 10.1136/pgmj.72.843.45 8746285
129. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. YZ Xue LX Wang HZ Liu XW Qi XH Wang HZ Ren, Cardiovasc Drugs Ther 2007 21 445 448 10.1007/s10557-007-6056-9 17955358
130. Mitochondrial dysfunction and neuromuscular disease. RA Nardin DR Johns, Muscle Nerve 2001 24 170 191 10.1002/1097-4598(200102)24:2<170::AID- MUS30>3.0.CO;2-0 11180201
131. Muscle carnitine levels in neuromuscular disease. PR Borum HP Broquist RJ Roelops, J Neurol Sci 1977 34 279 286 10.1016/0022-510X(77)90075-2 925714
132. Muscle carnitine palmityltransferase deficiency and myoglobinuria. S DiMauro PM DiMauro, Science 1973 182 929 931 10.1126/science.182.4115.929 4745596
133. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? PE Lheureux A Penaloza S Zahir M Gris, Crit Care 2005 9 431 440 10.1186/cc3742 16277730
134. Valproic acid associated abnormalities of carnitine metabolism. JV Murphy KM Marquardt AL Shug, Lancet 1985 1 820 821 10.1016/S0140-6736(85)91481-3 2858698
135. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. HA Spiller EP Krenzelok W Klein-Schwartz ML Winter JA Weber DR Sollee SA Bangh JR Griffith, J Toxicol Clin Toxicol 2000 38 755 760 10.1081/CLT-100102388 11192462
136. -2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. WA Watson TL Litovitz W Klein-Schwartz GC Rodgers Jr J Youniss N Reid WG Rouse RS Rembert D Borys, Am J Emerg Med 2004 22 335 404 10.1016/j.ajem.2004.06.001 15490384
137. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. DC DeVivo, Neurology 2002 58 507 508 11839873
138. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. SA Konig H Siemes F Blaker E Boenigk G Gross-Selbeck F Hanefeld N Haas B Kohler W Koelfen R Korinthenberg, et al. Epilepsia 1994 35 1005 1015 10.1111/j.1528-1157.1994.tb02546.x 7925143
139. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. H Siemes H Nau K Schultze W Wittfoht E Drews J Penzien U Seidel, Epilepsia 1993 34 332 346 10.1111/j.1528-1157.1993.tb02419.x 8453944
140. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. AA Al-Majed MM Sayed-Ahmed AA Al-Yahya AM Aleisa SS Al-Rejaie OA Al-Shabanah, Pharmacol Res 2006 53 278 286 10.1016/j.phrs.2005.12.005 16436331
141. Mitochondrial DNA repair and aging. BS Mandavilli JH Santos B Van Houten, Mutat Res 2002 509 127 151 12427535
142. Age-dependent decrease of carnitine content in muscle of mice and humans. M Costell JE O'Connor S Grisolia, Biochem Biophys Res Commun 1989 161 1135 1143 10.1016/0006-291X(89)91360-0 2742580
143. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. TM Hagen RT Ingersoll CM Wehr J Lykkesfeldt V Vinarsky JC Bartholomew MH Song BN Ames, Proc Natl Acad Sci USA 1998 95 9562 9566 10.1073/pnas.95.16.9562 9689120
144. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. J Liu E Head AM Gharib W Yuan RT Ingersoll TM Hagen CW Cotman BN Ames, Proc Natl Acad Sci USA 2002 99 2356 2361 10.1073/pnas.261709299 11854529
145. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. TM Hagen J Liu J Lykkesfeldt CM Wehr RT Ingersoll V Vinarsky JC Bartholomew BN Ames, Proc Natl Acad Sci USA 2002 99 1870 1875 10.1073/pnas.261708898 11854487
146. HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats. S Sugiyama, Biochem Mol Biol Int 1998 46 923 931 9861446
147. L-carnitine and alpha-lipoic acid improve age-associated decline in mitochondrial respiratory chain activity of rat heart muscle. S Sethumadhavan P Chinnakannu, J Gerontol A Biol Sci Med Sci 2006 61 650 659 16870625
148. Supplementation of L-carnitine improves mitochondrial enzymes in heart and skeletal muscle of aged rats. S Kumaran M Subathra M Balu C Panneerselvam, Exp Aging Res 2005 31 55 67 10.1080/03610730590882846 15842073
149. Age-associated deficit of mitochondrial oxidative phosphorylation in skeletal muscle: role of carnitine and lipoic acid. S Kumaran KS Panneerselvam S Shila K Sivarajan C Panneerselvam, Mol Cell Biochem 2005 280 83 89 10.1007/s11010-005-8234-z 16311908
150. L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. S Colucci G Mori S Vaira G Brunetti G Greco L Mancini GM Simone F Sardelli A Koverech A Zallone M Grano, Calcif Tissue Int 2005 76 458 465 10.1007/s00223-004-0147-4 15906015
151. Levels of carnitines in brain and other tissues of rats of different ages: effect of acetyl-L-carnitine administration. F Maccari A Arseni P Chiodi MT Ramacci L Angelucci, Exp Gerontol 1990 25 127 134 10.1016/0531-5565(90)90043- 2 2369927
152. L: -carnitine fumarate and isovaleryl-L: -carnitine fumarate accelerate the recovery of bone volume/total volume ratio after experimetally induced osteoporosis in pregnant mice. N Patano L Mancini MP Settanni M Strippoli G Brunetti G Greco R Tamma R Vergari F Sardelli A Koverech S Colucci A Zallone M Grano, Calcif Tissue Int 2008 82 221 228 10.1007/s00223-008-9109-6 18265928
153. Fatty acid oxidation in bone tissue and bone cells in culture. Characterization and hormonal influences. G Adamek R Felix HL Guenther H Fleisch, Biochem J 1987 248 129 137 3325035
154. Dietary l-carnitine supplementation improves bone mineral density by suppressing bone turnover in aged ovariectomized rats. S Hooshmand A Balakrishnan RM Clark KQ Owen SI Koo BH Arjmandi, Phytomedicine 2008 15 595 601 10.1016/j.phymed.2008.02.026 18539446
155. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. RM Corrales L Luo EY Chang SC Pflugfelder, Cornea 2008 27 574 579 10.1097/ICO.0b013e318165b19e 18520508
156. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. CS De Paiva AL Villarreal RM Corrales HT Rahman VY Chang WJ Farley ME Stern JY Niederkorn DQ Li SC Pflugfelder, Invest Ophthalmol Vis Sci 2007 48 2553 2560 10.1167/iovs.07-0069 17525184
157. Impaired functional visual acuity of dry eye patients. E Goto Y Yagi Y Matsumoto K Tsubota, Am J Ophthalmol 2002 133 181 186 10.1016/S0002-9394(01) 01365-4 11812420 (Pubitemid 34072045)
158. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. SC Pflugfelder SC Tseng O Sanabria H Kell CG Garcia C Felix W Feuer BL Reis, Cornea 1998 17 38 56 10.1097/00003226-199801000-00007 9436879
159. Effect of compatible solutes on transepithelial electrical resistance and uptake in primary rabbit corneal epithelial cell layers model. P Simmons J Chang-Lin Q Chung J Vehige D Welty, Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Fort Lauderdale, Florida, USA 2007
160. Expression and localization of carnitine/organic cation transporter OCTN1 and OCTN2 in ocular epithelium. Q Garrett S Xu PA Simmons J Vehige JL Flanagan MD Willcox, Invest Ophthalmol Vis Sci 2008 49 4844 4849 10.1167/iovs.07-1528 18641280
161. L-carnitine and short chain ester in tears from patients with dry eye. N Pescosolido B Imperatrice A Koverech M Messano, Optom Vis Sci 2009 86 132 138 10.1097/OPX.0b013e318194e767 19156017
162. Human tear film electrolyte concentrations in health and dry-eye disease. JP Gilbard, Int Ophthalmol Clin 1994 34 27 36 10.1097/00004397-199403410-00005 8169071
163. In experimental diabetes the decrease in the eye of lens carnitine levels is an early important and selective event. P Pessotto R Liberati O Petrella L Romanelli M Calvani G Peluso, Exp Eye Res 1997 64 195 201 10.1006/exer.1996.0188 9176053
164. Carnitine palmitoyltransferase I and Acyl-CoA dehydrogenase 9 in retina: insights of retinopathy in mitochondrial trifunctional protein defects. E Roomets T Kivela T Tyni, Invest Ophthalmol Vis Sci 2008 49 1660 1664 10.1167/iovs.07-1094 18385088
165. Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy. T Tyni T Kivela M Lappi P Summanen E Nikoskelainen H Pihko, Ophthalmology 1998 105 810 824 10.1016/S0161-6420(98)95019-9 9593380
166. Dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD). A case report and survey. M Gillingham S Van Calcar D Ney J Wolff C Harding, J Inherit Metab Dis 1999 22 123 131 10.1023/A:1005437616934 10234607
167. Ophthalmic pathology in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation. T Tyni H Pihko T Kivela, Curr Eye Res 1998 17 551 559 10.1080/02713689808951227 9663844
168. Carnitine deficiency disorders in children. CA Stanley, Ann N Y Acad Sci 2004 1033 42 51 10.1196/annals.1320.004 15591002